Sean P. Nolan

Sean P. Nolan has served as Chief Executive Officer at Taysha Gene Therapies since 2022 and as Chairman of the Board of Directors since 2020.

Sean is an accomplished biopharmaceutical executive with over 30 years of experience across commercial operations, global marketing, and corporate and business development. He has a proven record of scaling and leading companies from early-stage development through global commercialization. Before joining Taysha, Sean served as President and Chief Executive Officer at AveXis and was a member of the company’s Board of Directors. Under Sean’s leadership, his team developed Zolgensma for the treatment of spinal muscular atrophy, the first U.S. FDA approved one-time gene therapy to treat a monogenic CNS disorder, and scaled AveXis into a fully integrated, publicly traded company that was acquired by Novartis. Before AveXis, Sean served as Chief Business Officer at InterMune, where he built and led the U.S. commercial, business development and global marketing functions through the successful launch of pirfenidone for the treatment of idiopathic pulmonary fibrosis and the company’s acquisition by Roche. Sean previously served as Chief Commercial Officer at Reata Pharmaceuticals and held leadership roles in sales and marketing at both Lundbeck and Abbott Laboratories, contributing to the approval and commercialization of multiple drugs and biological products.

Sean serves as Chairman of the Board of Directors at Affinia Therapeutics, Encoded Therapeutics and Jaguar Gene Therapy, LLC. He is also a member of the Board of Directors at Ventas and John Carroll University. Sean serves as an advisor to the Goldman Sachs Life Sciences Fund.

Sean earned a B.A. in biology from John Carroll University.